EGFR and non-small cell lung carcinoma: Of the total 1341 patients, the PD-L1 expression levels were < 1 for 43.4% of patients, between 1 and 50 for 26.5% of patients, and >50 for 30.1% of patients (866 of patients had missing PD-L1 expression levels since PD-L1 testing was not part of the clinical routine among NSCLC patients until 2015), with no large variations observed across stages or across EGFR mutation status (PD-L1 data stratified by EGFR mutation status not shown).